Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer
NCT ID: NCT02381912
Last Updated: 2016-03-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
210 participants
OBSERVATIONAL
2015-03-31
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study
NCT07339761
Patient-reported Outcomes in Bladder Cancer
NCT03584659
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
NCT02379429
Bladder Cancer Patient-Reported Outcomes
NCT01090388
Diagnostic Performance and Predictive Capacity of Immediate Urine Cytology After Transurethral Resection of Non-Muscle Invasive Bladder Cancer; A Prospective Study
NCT04194112
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hematuria - NMIBC
Primary hematuria due to NMIBC.
EORTC QLQ-C30 and EORTC BLS-24 questionnaire
Questionnaires answered at baseline and 4 months follow up.
Hematuria - other cause
Other non-malignant cause of hematuria.
EORTC QLQ-C30 and EORTC BLS-24 questionnaire
Questionnaires answered at baseline and 4 months follow up.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
EORTC QLQ-C30 and EORTC BLS-24 questionnaire
Questionnaires answered at baseline and 4 months follow up.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men and women older or equal to 40 years of age
* Signed informed consent statement
Exclusion Criteria
* Patients with recurrent hematuria and known causative disease
* Already known urogenital cancer
* Previous massive pelvic surgery or pelvic radiotherapy
* TUR-P within the last 2 months
* Participants diagnosed with tumors originating from the ureters, renal pelvis and kidney, and bladder tumors at T stage more than or equal to T1b.
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Herlev Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peter Busch Østergren
MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter B Østergren, MD
Role: PRINCIPAL_INVESTIGATOR
Herlev Hospital, Department of Urology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Herlev Hospital
Herlev, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kowalkowski MA, Chandrashekar A, Amiel GE, Lerner SP, Wittmann DA, Latini DM, Goltz HH. Examining sexual dysfunction in non-muscle-invasive bladder cancer: results of cross-sectional mixed-methods research. Sex Med. 2014 Aug;2(3):141-51. doi: 10.1002/sm2.24.
van der Aa MN, Bekker MD, van der Kwast TH, Essink-Bot ML, Steyerberg EW, Zwarthoff EC, Sen FE, Elzevier HW. Sexual function of patients under surveillance for bladder cancer. BJU Int. 2009 Jul;104(1):35-40. doi: 10.1111/j.1464-410X.2008.08333.x. Epub 2009 Jan 14.
Goossens-Laan CA, Kil PJ, Ruud Bosch JL, De Vries J. Pre-diagnosis quality of life (QoL) in patients with hematuria: comparison of bladder cancer with other causes. Qual Life Res. 2013 Mar;22(2):309-15. doi: 10.1007/s11136-012-0163-1. Epub 2012 Mar 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SSBC-2015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.